Carbapenem-resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?
Gladys V B do PradoElisa Donalisio Teixeira MendesRoberta C R MartinsLauro V Perdigão-NetoMaristela Pinnheiro FreireFernanda SpadãoVictor A C de Castro LimaFlavia RossiThais GuimarãesAnna S LevinVanderson RochaSilvia F CostaPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2021)
Surveillance programs have been reporting decreasing rates of carbapenem-sensitivity in Serratia marcescens, leading to a concern regarding the few remaining therapeutic options to treat these multidrug-resistant (MDR) organisms. Here, we describe a case series of 11 stem cell hematopoietic transplantation patients infected (N = 6) or colonized (N = 5) by carbapenem-resistant S marcescens (CrSm) from 2010 to 2013. The comorbidities found were acute renal insufficiency (3/11), neutropenia (7/11), and mucositis (8/11), and the mortality rate was 64%. KPC was the most prevalent carbapenemase detected (8/11) and tigecycline and gentamicin were the antimicrobials used as treatment.
Keyphrases
- klebsiella pneumoniae
- multidrug resistant
- gram negative
- end stage renal disease
- acinetobacter baumannii
- stem cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- public health
- prognostic factors
- acute myeloid leukemia
- drug resistant
- escherichia coli
- peritoneal dialysis
- cardiovascular disease
- liver failure
- cardiovascular events
- bone marrow
- cell therapy
- electronic health record